These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2277605)

  • 1. Respective roles of 25 hydroxy-vitamin D, PTH, phosphate and renal function for the 1-alpha-hydroxylase activity in primary hyperparathyroidism.
    Frølich A; Nielsen BF; Transbøl I
    Miner Electrolyte Metab; 1990; 16(4):210-5. PubMed ID: 2277605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function.
    Moosgaard B; Vestergaard P; Heickendorff L; Mosekilde L
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):35-42. PubMed ID: 17201799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the plasma concentration of 25-hydroxyvitamin D determine the level of 1,25-dihydroxyvitamin D in primary hyperparathyroidism?
    Frølich A; Storm T; Thode J
    Miner Electrolyte Metab; 1996; 22(4):203-6. PubMed ID: 8807622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area].
    Karlsson SL; Indridason OS; Franzson L; Sigurdsson G
    Laeknabladid; 2005 Feb; 91(2):161-9. PubMed ID: 16155312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of effect of 24,25-dihydroxycholecalciferol on serum immunoreactive PTH in patients with persistent hyperparathyroidism after renal transplantation.
    Friedlander MA; Horst RL; Hawker CD
    Clin Nephrol; 1984 Oct; 22(4):206-10. PubMed ID: 6391769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.
    Lu KC; Shieh SD; Chyr SH; Lin SH; Li BL; Diang LK; Chen WQ; Lin YF
    Diabetes Res; 1993; 22(3):97-104. PubMed ID: 8076446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical importance of disorders of vitamin D metabolism].
    Flury W
    Schweiz Med Wochenschr; 1978 Jan; 108(4):129-33. PubMed ID: 341302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction.
    Yendt ER; Kovacs KA; Jones G
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):855-63. PubMed ID: 18419790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of parathyroid hormone and vitamin D in essential hypertension.
    Young EW; Morris CD; Holcomb S; McMillan G; McCarron DA
    Am J Hypertens; 1995 Oct; 8(10 Pt 1):957-64. PubMed ID: 8845076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the understanding of the metabolism and functions of vitamin D.
    Ross FP; Henry HL
    Clin Orthop Relat Res; 1980 Jun; (149):249-67. PubMed ID: 6250754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting calcium metabolism in disorders of the kidney.
    Favus MJ
    Ann Clin Lab Sci; 1981; 11(4):327-32. PubMed ID: 7023346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peculiarities of vitamin D and of the calcium and phosphate homeostatic system in horses.
    Breidenbach A; Schlumbohm C; Harmeyer J
    Vet Res; 1998; 29(2):173-86. PubMed ID: 9601149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism.
    LoCascio V; Adami S; Galvanini G; Ferrari M; Cominacini L; Tartarotti D
    N Engl J Med; 1985 Oct; 313(18):1123-5. PubMed ID: 3840228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Review of the concept of vitamin D "sufficiency and insufficiency"].
    Gómez Alonso C; Naves Díaz M; Rodríguez García M; Fernández Martín JL; Cannata Andía JB
    Nefrologia; 2003; 23 Suppl 2():73-7. PubMed ID: 12778859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid hormone and 25-hydroxy vitamin D3: synergistic and antagonistic effects on renal phosphate transport.
    Puschett JB; Beck WS
    Science; 1975 Oct; 190(4213):473-5. PubMed ID: 1166316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate phosphate excretion in idiopathic hypercalciuria: the key to a common cause and future treatment?
    Williams CP; Child DF; Hudson PR; Soysa LD; Davies GK; Davies MG; De Bolla AR
    J Clin Pathol; 1996 Nov; 49(11):881-8. PubMed ID: 8944605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of parathyroid extract on renal vitamin D hydroxylases in Japanese quail.
    Baksi SN; Kenny AD
    Pharmacology; 1979; 18(4):169-74. PubMed ID: 461495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism.
    Gray RW; Wilz DR; Caldas AE; Lemann J
    J Clin Endocrinol Metab; 1977 Aug; 45(2):299-306. PubMed ID: 885994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained activation of renal N-methyl-D-aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT.
    Parisi E; Bozic M; Ibarz M; Panizo S; Valcheva P; Coll B; Fernández E; Valdivielso JM
    Am J Physiol Endocrinol Metab; 2010 Nov; 299(5):E825-31. PubMed ID: 20823451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.